Bidirectional Association Between COVID-19 and Mental Health Disorders: A Narrative Review
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 11 No. 3 (2021),
18 July 2021
,
Page 34101
https://doi.org/10.32598/ijmtfm.v11i3.34104
Abstract
Background: Fear, anxiety, and stress are natural reactions of the human body to unpredictable and potentially threatening conditions. Currently, individuals are encountering Coronavirus Disease 2019 (COVID-19) pandemic; it is caused by a virulent, partially unknown pathogen with high transmissibility, recognized as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is conceivable to experience anxiety, stress, and subsequent mental health disorders during the pandemic. This narrative review provided a brief overview of mechanisms involved in COVID-19 and mental health disorders as well as the bidirectional association between them.
Methods: Scientific electronic databases, such as PubMed, Scopus, Web of Science, and Google Scholar were thoroughly searched, based on different keywords in this study.
Results: Lifestyle changes and isolation for breaking the chain of infection facilitate mental health disorders development more than before. Since the onset of the pandemic, the prevalence of mental health disorders has significantly increased. Moreover, studies suggested that the incidence of COVID-19 and the progression of the disease to a severe and life-threatening stage is higher in individuals with a history of mental health disorders. Inflammation is caused by, also may cause mental health disorders. Besides, COVID-19 is associated with cytokine storm and subsequent inflammation.
Conclusion: There seems to be a bidirectional association between COVID-19 and mental health disorders, in which inflammation acts as an adaptor.
- Coronavirus Disease 2019 (COVID-19)
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV- 2)
- Mental disorders
- Cytokine release syndrome
- Inflammation
How to Cite
References
Talaie H, Hosseini SM, Nazari M, Fakhri Y, Mousavizadeh A, Vatanpour H, et al. Is there any potential management against COVID-19? A systematic review and meta-analysis. Daru J Pharm Sci. 2020; 28(2):765-77. [DOI:10.1007/s40199-020-00367-4] [PMID] [PMCID]
Talaie H, Nazari M, Hosseini SM, Mousavizadeh A, Alavi-Darazam I, Vatanpour H. The impact of current COVID-19 therapeutics on patients’ clinical improvements based on disease severity; A systematic review. Int Pharm Acta. 2020; 3(1):e10. [DOI:10.22037/ipa.v3i1.32431]
Merad M, Martin JC. Author correction: Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat Rev Immunol. 2020; 20(7):448. [DOI:10.1038/s41577-020-0353-y] [PMID] [PMCID]
Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020; 181(5):1036-45.e9. [DOI:10.1016/j.cell.2020.04.026] [PMID] [PMCID]
World Health Organization (WHO). Estimating mortality from COVID-19 [Internet]. 2020 [Updated 2020 August 4]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1
Perez-Saez FJ, Lauer SA, Kaiser L, Regard S, Delaporte E, Guessous I, et al. Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland. Lancet Infect Dis. 2021; 21(4):e69-70. [DOI:10.1016/S1473-3099(20)30584-3] [PMID] [PMCID]
Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and comorbidities: A systematic review and meta-analysis. Postgrad Med. 2020:1-7. [DOI:10.1080/00325481.2020.1786964] [PMID]
Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: A systematic review and meta-analysis. Int J Public Health. 2020; 65(5):533-46. [DOI:10.1007/s00038-020-01390-7] [PMID] [PMCID]
Hu Y, Chen Y, Zheng Y, You C, Tan J, Hu L, et al. Factors related to mental health of inpatients with COVID-19 in Wuhan, China. Brain Behav Immun. 2020; 89:587-93. [DOI:10.1016/j.bbi.2020.07.016] [PMID] [PMCID]
Asmundson GJG, Paluszek MM, Landry CA, Rachor GS, McKay D, Taylor S. Do pre-existing anxiety-related and mood disorders differentially impact COVID-19 stress responses and coping? J Anxiety Disord. 2020; 74:102271. [DOI:10.1016/j.janxdis.2020.102271] [PMID] [PMCID]
Zandifar A, Badrfam R. Iranian mental health during the COVID-19 epidemic. Asian J Psychiatr. 2020; 51:101990. [DOI:10.1016/j.ajp.2020.101990] [PMID] [PMCID]
Winkler P, Formanek T, Mlada K, Kagstrom A, Mohrova Z, Mohr P, et al. Increase in prevalence of current mental disorders in the context of COVID-19: Analysis of repeated nationwide cross-sectional surveys. Epidemiol Psychiatr Sci. 2020; 29:e173. [DOI:10.1017/S2045796020000888] [PMID] [PMCID]
Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020; 87:100-6. [DOI:10.1016/j.bbi.2020.04.069] [PMID] [PMCID]
Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020; 89:594-600. [DOI:10.1016/j.bbi.2020.07.037] [PMID] [PMCID]
Kempuraj D, Selvakumar GP, Ahmed ME, Raikwar SP, Thangavel R, Khan A, et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020; 26(5-6):402-14. [DOI:10.1177/1073858420941476] [PMID]
Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: What comes first? Ann N Y Acad Sci. 2019; 1437(1):57-67. [DOI:10.1111/nyas.13712] [PMID]
Leonard BE. Inflammation and depression: A causal or coincidental link to the pathophysiology? Acta Neuropsychiatr. 2018; 30(1):1-16. [DOI:10.1017/neu.2016.69] [PMID]
Hiles SA, Baker AL, de Malmanche T, McEvoy M, Boyle M, Attia J. The role of inflammatory markers in explaining the association between depression and cardiovascular hospitalisations. J Behav Med. 2015; 38(4):609-19. [DOI:10.1007/s10865-015-9637-2] [PMID]
Masih J, Verbeke W. Immune system function and its relation to depression: How exercise can alter the immune system-depression dynamics. J Depress Anxiety. 2018; 7(4):1-7. [DOI:10.4172/2167-1044.1000325]
Rice F, van den Bree MBM, Thapar A. A population-based study of anxiety as a precursor for depression in childhood and adolescence. BMC Psychiatry. 2004; 4(1):43. [DOI:10.1186/1471-244X-4-43] [PMID] [PMCID]
Kraines MA, White EJ, Grant DM, Wells TT. Social anxiety as a precursor for depression: Influence of interpersonal rejection and attention to emotional stimuli. Psychiatry Res. 2019; 275:296-303. [DOI:10.1016/j.psychres.2019.04.001] [PMID]
Baglioni C, Riemann D. Is chronic insomnia a precursor to major depression? Epidemiological and biological findings. Curr Psychiatry Rep. 2012; 14(5):511-8. [DOI:10.1007/s11920-012-0308-5] [PMID]
Boudewyn AC, Liem JH. Childhood sexual abuse as a precursor to depression and self-destructive behavior in adulthood. J Trauma Stress. 1995; 8(3):445-59. [DOI:10.1002/jts.2490080307] [PMID]
Robinson RG, Jorge RE. Post-stroke depression: A review. Am J Psychiatry. 2016; 173(3):221-31. [DOI:10.1176/appi.ajp.2015.15030363] [PMID]
Patel S. Danger-Associated Molecular Patterns (DAMPs): The derivatives and triggers of inflammation. Curr Allergy Asthma Rep. 2018; 18(11):63. [DOI:10.1007/s11882-018-0817-3] [PMID]
Franklin TC, Xu C, Duman RS. Depression and sterile inflammation: Essential role of danger associated molecular patterns. Brain Behav Immun. 2018; 72:2-13. [DOI:10.1016/j.bbi.2017.10.025] [PMID]
Santecchia I, Ferrer MF, Vieira ML, Gómez RM, Werts C. Phagocyte escape of leptospira: The role of TLRs and NLRs. Front Immunol. 2020; 11:571816. [DOI:10.3389/fimmu.2020.571816] [PMID] [PMCID]
Figueroa-Hall LK, Paulus MP, Savitz J. Toll-like receptor signaling in depression. Psychoneuroendocrinology. 2020; 121:104843. [DOI:10.1016/j.psyneuen.2020.104843] [PMID]
Bueno BG, Caso JR, Madrigal JLM, Leza JC. Innate immune receptor Toll-like receptor 4 signalling in neuropsychiatric diseases. Neurosci Biobehav Rev. 2016; 64:134-47. [DOI:10.1016/j.neubiorev.2016.02.013] [PMID]
Cheng Y, Pardo M, de Souza Armini R, Martinez A, Mouhsine H, Zagury JF, et al. Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain Behav Immun. 2016; 53:207-22. [DOI:10.1016/j.bbi.2015.12.012] [PMID] [PMCID]
Hajebrahimi B, Bagheri M, Hassanshahi G, Nazari M, Bidaki R, Khodadadi H, et al. The adapter proteins of TLRs, TRIF and MYD88, are upregulated in depressed individuals. Int J Psychiatry Clin Pract. 2014; 18(1):41-4. [DOI:10.3109/13651501.2013.859708] [PMID]
Dahl J, Ormstad H, Aass HCD, Malt UF, Bendz LT, Sandvik L, et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. 2014; 45:77-86. [DOI:10.1016/j.psyneuen.2014.03.019] [PMID]
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010; 67(5):446-57. [DOI:10.1016/j.biopsych.2009.09.033] [PMID]
Fan N, Luo Y, Ou Y, He H. Altered serum levels of TNF‐α, IL‐6, and IL‐18 in depressive disorder patients. Hum Psychopharmacol. 2017; 32(4):e2588. [DOI:10.1002/hup.2588] [PMID]
Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017; 17(4):233-47. [DOI:10.1038/nri.2017.1] [PMID]
Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood trauma and depression: Insights from HPA axis studies in humans. Psychoneuroendocrinology. 2008; 33(6):693-710. [DOI:10.1016/j.psyneuen.2008.03.008] [PMID]
Bauer ME, Papadopoulos A, Poon L, Perks P, Lightman SL, Checkley S, et al. Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology. 2003; 28(1):49-65. [DOI:10.1016/S0306-4530(02)00009-4] [PMID]
Horowitz MA, Zunszain PA. Neuroimmune and neuroendocrine abnormalities in depression: Two sides of the same coin. Ann N Y Acad Sci. 2015; 1351(1):68-79. [DOI:10.1111/nyas.12781] [PMID]
Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009; 65(9):732-41. [DOI:10.1016/j.biopsych.2008.11.029] [PMID] [PMCID]
Hori H, Kim Y. Inflammation and post‐traumatic stress disorder. Psychiatry Clin Neurosci. 2019; 73(4):143-53. [DOI:10.1111/pcn.12820] [PMID]
Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016; 16(1):22-34. [DOI:10.1038/nri.2015.5] [PMID] [PMCID]
Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology. 2013; 38(9):1609-16. [DOI:10.1038/npp.2013.71] [PMID] [PMCID]
O’Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice. Mol Psychiatry. 2009; 14(5):511-22. [DOI:10.1038/sj.mp.4002148] [PMID] [PMCID]
Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-αlpha: Relationship to CNS immune responses and depression. Mol Psychiatry. 2010; 15(4):393-403. [DOI:10.1038/mp.2009.116] [PMID] [PMCID]
Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020; 21(5):343-60. [DOI:10.1631/jzus.B2000083] [PMID] [PMCID]
Behrens EM, Koretzky GA. Review: Cytokine storm syndrome: Looking toward the precision medicine era. Arthritis Rheumatol. 2017; 69(6):1135-43. [DOI:10.1002/art.40071] [PMID]
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020; 395(10223):507-13. [DOI:10.1016/S0140-6736(20)30211-7] [PMID] [PMCID]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5]
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017; 39(5):529-39. [DOI:10.1007/s00281-017-0629-x] [PMID] [PMCID]
Li Y, Chen M, Cao H, Zhu Y, Zheng J, Zhou H. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. Microbes Infect. 2013; 15(2):88-95. [DOI:10.1016/j.micinf.2012.10.008] [PMID] [PMCID]
Lau SKP, Lau CCY, Chan KH, Li CPY, Chen H, Jin DY, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment. J Gen Virol. 2013; 94(Pt 12):2679-90. [DOI:10.1099/vir.0.055533-0] [PMID]
Oldstone MBA, Rosen H. Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol. 2014; 378:129-47. [DOI:10.1007/978-3-319-05879-5_6] [PMID] [PMCID]
Gao YM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med. 2021; 289(2):147-61. [DOI:10.1111/joim.13144] [PMID] [PMCID]
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2):271-80.e8. [DOI:10.1016/j.cell.2020.02.052] [PMID] [PMCID]
Eguchi S, Kawai T, Scalia R, Rizzo V. Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology. Hypertension. 2018; 71(5):804-10. [DOI:10.1161/HYPERTENSIONAHA.118.10266] [PMID] [PMCID]
Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity: Insights from the interleukin 6 family of cytokines. Immunity. 2019; 50(4):812-31. [DOI:10.1016/j.immuni.2019.03.027] [PMID]
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-9. [DOI:10.1172/JCI137244] [PMID] [PMCID]
Wong P, Pamer EG. CD8 T cell responses to infectious pathogens. Annu Rev Immunol. 2003; 21:29-70. [DOI:10.1146/annurev.immunol.21.120601.141114] [PMID]
Bermejo-Martin JF, de Lejarazu RO, Pumarola T, Rello J, Almansa R, Ramírez P, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009; 13(6):R201. [DOI:10.1186/cc8208] [PMID] [PMCID]
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-2. [DOI:10.1016/S2213-2600(20)30076-X] [PMID] [PMCID]
Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: The REPROGRAM consortium position paper. Front Immunol. 2020; 11:1648. [DOI:10.3389/fimmu.2020.01648] [PMID] [PMCID]
Alexopoulos H, Magira E, Bitzogli K, Kafasi N, Vlachoyiannopoulos P, Tzioufas A, et al. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients. Neurol Neuroimmunol Neuroinflamm. 2020; 7(6):e893. [DOI:10.1212/NXI.0000000000000893] [PMID] [PMCID]
Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016; 13(1):3-10. [DOI:10.1038/cmi.2015.74] [PMID] [PMCID]
Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: Retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021; 8(2):130-40. [DOI: 10.1016/S2215-0366(20)30462-4]
Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax. 2013; 68(2):171-6. [DOI:10.1136/thoraxjnl-2012-202480] [PMID]
Fana M, Pérez ST, Fernández-Macías E. Employment impact of Covid-19 crisis: From short term effects to long terms prospects. J Ind Bus Econ. 2020; 47:391-410. [DOI:10.1007/s40812-020-00168-5] [PMCID]
Poudel K, Subedi P. Impact of COVID-19 pandemic on socioeconomic and mental health aspects in Nepal. Int J Soc Psychiatry. 2020; 66(8):748-55. [DOI:10.1177/0020764020942247] [PMID] [PMCID]
Postolache TT, Benros ME, Brenner LA. Targetable biological mechanisms implicated in emergent psychiatric conditions associated with SARS-CoV-2 infection. JAMA Psychiatry. 2021; 78(4):353-4. [DOI:10.1001/jamapsychiatry.2020.2795] [PMID]
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26(7):1017-32. [DOI:10.1038/s41591-020-0968-3] [PMID]
Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19. J Med Virol. 2020; 92(7):791-6 [DOI:10.1002/jmv.25770] [PMID] [PMCID]
Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7(7):611-27. [DOI:10.1016/S2215-0366(20)30203-0] [PMID] [PMCID]
Dantzer R. Neuroimmune interactions: From the brain to the immune system and vice versa. Physiol Rev. 2018; 98(1):477-504. [DOI:10.1152/physrev.00039.2016] [PMID] [PMCID]
Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020; 87:34-9. [DOI:10.1016/j.bbi.2020.04.027] [PMID] [PMCID]
Wang QQ, Xu R, Volkow ND. Increased risk of COVID‐19 infection and mortality in people with mental disorders: Analysis from electronic health records in the United States. World Psychiatry. 2021; 20(1):124-30. [DOI:10.1002/wps.20806] [PMID] [PMCID]
Vogelzangs N, Beekman ATF, de Jonge P, Penninx BWJH. Anxiety disorders and inflammation in a large adult cohort. Transl Psychiatry. 2013; 3(4):e249. [DOI:10.1038/tp.2013.27] [PMID] [PMCID]
Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: A nested case-control and survival analysis in a population-based cohort. Thorax. 2013; 68(2):163-70. [DOI:10.1136/thoraxjnl-2012-202374] [PMID]
Talaie H, Abdollahi M, Pajoumand A, Panahandeh R, Barari B, Baeeri M. Alteration of serum levels of interlukin 1 and tumor necrosis factor in depression independent of treatment or overdose of tricyclic antidepressants. Iran J Toxicol. 2009; 2(3):228-33. http://ijt.arakmu.ac.ir/article-1-73-en.html
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm’in COVID-19. J Infect. 2020; 80(6):607-13. [DOI:10.1016/j.jinf.2020.03.037] [PMID] [PMCID]
Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: A meta‐analysis of 82 studies. Acta Psychiatr Scand. 2017; 135(5):373-87. [DOI:10.1111/acps.12698] [PMID]
Renna ME, O’Toole MS, Spaeth PE, Lekander M, Mennin DS. The association between anxiety, traumatic stress, and obsessive-compulsive disorders and chronic inflammation: A systematic review and meta‐analysis. Depress Anxiety. 2018; 35(11):1081-94. [DOI:10.1002/da.22790] [PMID]
Poletti S, Leone G, Hoogenboezem TA, Ghiglino D, Vai B, de Wit H, et al. Markers of neuroinflammation influence measures of cortical thickness in bipolar depression. Psychiatry Res Neuroimaging. 2019; 285:64-6. [DOI:10.1016/j.pscychresns.2019.01.009] [PMID]
Liukkonen T, Räsänen P, Jokelainen J, Leinonen M, Järvelin MR, Meyer-Rochow VB, et al. The association between anxiety and C-Reactive Protein (CRP) levels: Results from the Northern Finland 1966 birth cohort study. Eur Psychiatry. 2011; 26(6):363-9. [DOI:10.1016/j.eurpsy.2011.02.001] [PMID]
Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, =et al. Gender differences in patients with COVID-19: Focus on severity and mortality. Front Public Health. 2020; 8:152. [DOI:10.3389/fpubh.2020.00152] [PMID] [PMCID]
- Abstract Viewed: 358 times
- pdf Downloaded: 219 times